SEC Form 4 · accession 0000899243-18-009133
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David W Beier
Director
Period of report
Apr 1, 2018
Accepted (ET)
Apr 2, 2018 · 8:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $2.10 | Apr 1, 2018 | A | 40,000 | A | — | Apr 1, 2028 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Represents the closing sale price per share of the Issuer's common stock as reported on the Nasdaq Global Select Market on the trading day immediately prior to the date of grant.
- F2The option vests as to 1/8th of the shares on June 30, 2018 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the Issuer.
Remarks
Ex. 24: Limited Power of Attorney